Press release summary
BioAgilytix has opened a purpose-designed 360biolabs facility in Sydney’s Macquarie Park Innovation District, expanding its Australian bioanalytical operations beyond Melbourne and Brisbane.
The biosafety level 2 laboratory is set up for peripheral blood mononuclear cell isolation and flow cytometry, with dedicated areas for sample reception and storage. It also includes ultra-low-temperature freezers, vapor-phase nitrogen cryostorage, and continuous temperature monitoring. BioAgilytix said the Sydney team will support assay development and validation for early-phase clinical studies, while shared procedures, instrumentation, and quality systems are intended to make assays transferable across the company’s laboratories in Australia, Europe, and the United States. The facility has received National Association of Testing Authorities accreditation to ISO/IEC 17025.
For laboratory readers, the expansion is relevant because time-sensitive clinical specimens can lose value when processing is delayed or storage conditions are inconsistent. Local cell-processing capacity, monitored cold storage, and standardized transfer procedures can reduce operational risk while supporting continuity from first-in-human studies into larger global programs. The release did not disclose capacity, staffing levels, or project volume, so the operational impact will depend on implementation.
Original release: BioAgilytix, Oct. 26, 2026.
Leave a Reply